^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mobilan (M-VM3)

    i
    Other names: M-VM3, recombinant non-replicating adenovirus, MVAME03
    Associations

    News

    Trials
    Company:
    Statera BioPharma
    Drug class:
    TLR5 agonist
    Related drugs:
    Associations

    News

    Trials
    over4years
    First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. (PubMed, Oncotarget)
    Therefore, Mobilan is well-tolerated and induces the expected pharmacodynamic response in humans. These results support further clinical development of Mobilan as a novel immunotherapy for prostate cancer.
    Clinical • P1 data • PK/PD data • Journal
    |
    IL6 (Interleukin 6)
    |
    Mobilan (M-VM3)